German drugmaker Boehringer Ingelheim is considering the sale of its U.S. generics unit Roxane Labs for as much as 2 billion euros ($2.36 billion), Bloomberg said, citing people with knowledge of the matter.
Roxane Labs
Breaking News
German drugmaker Boehringer Ingelheim is considering the sale of its U.S. generics unit Roxane Labs for as much as 2 billion euros ($2.36 billion), Bloomberg said, citing people with knowledge of the matter.
